Cart
sales@molnova.com
ERK5-IN-5
CAS No. 2318792-30-0
ERK5-IN-5( —— )
Catalog No. M37092 CAS No. 2318792-30-0
ERK5-IN-5 is a potent extracellular signal-regulated kinase 5 (ERK5) inhibitor with anticancer activity and potential anticonvulsant activity that inhibits A549 cell proliferation.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 2MG | 107 | In Stock |
|
| 5MG | 180 | In Stock |
|
| 10MG | 278 | In Stock |
|
| 25MG | 561 | In Stock |
|
| 50MG | 897 | In Stock |
|
| 100MG | 1423 | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | 2762 | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameERK5-IN-5
-
NoteResearch use only, not for human use.
-
Brief DescriptionERK5-IN-5 is a potent extracellular signal-regulated kinase 5 (ERK5) inhibitor with anticancer activity and potential anticonvulsant activity that inhibits A549 cell proliferation.
-
DescriptionERK5-IN-5 (compound 4a) is an ERK5 kinase inhibitor with anticancer activity. ERK5-IN-5 exhibits good anti-proliferative activity with the IC50 value of 6.23 μg/mL for A549 cells.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayMAPK/ERK Signaling
-
TargetERK
-
RecptorERK
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number2318792-30-0
-
Formula Weight337.8
-
Molecular FormulaC19H16ClN3O
-
Purity>98% (HPLC)
-
SolubilityIn Vitro:?DMSO : 100 mg/mL (296.03 mM; Ultrasonic )
-
SMILESO=C(C1=CC=C(Cl)C=C1)N2CC=C(C3=CNC=4N=CC=CC43)CC2
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Qin Zhang, et al. Design, synthesis and SAR of novel 7-azaindole derivatives as potential Erk5 kinase inhibitor with anticancer activity. Bioorg Med Chem. 2023 Oct 14:95:117503. ?
molnova catalog
related products
-
NMDA
N-Methyl-D-aspartic acid is an amino acid that, as the D-isomer, is the defining agonist for the NMDA receptor subtype of glutamate receptors.
-
FR 180204
FR 180204 is a potent, selective, ATP-competitive ERK inhibitor with Ki of 0.31 and 0.14 uM for ERK1 and ERK2, respectively.
-
GDC-0994
GDC-0994 is a potent, orally available ERK1/2 inhibitor with IC50 of 1.1 nM and 0.3 nM, respectively. Phase 1.
